Stephen K. Doberstein

2015

In 2015, Stephen K. Doberstein earned a total compensation of $1.2M as Senior Vice President and Chief Research and Development Officer at Nektar Therapeutics, a 46% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$198,300
Option Awards$127,085
Salary$495,800
Stock Awards$326,548
Other$13,054
Total$1,161,287

Doberstein received $495.8K in salary, accounting for 43% of the total pay in 2015.

Doberstein also received $198.3K in non-equity incentive plan, $127.1K in option awards, $326.5K in stock awards and $13.1K in other compensation.

Rankings

In 2015, Stephen K. Doberstein's compensation ranked 7,213th out of 13,638 executives tracked by ExecPay. In other words, Doberstein earned more than 47.1% of executives.

ClassificationRankingPercentile
All
7,213
out of 13,638
47th
Division
Manufacturing
2,715
out of 5,187
48th
Major group
Chemicals And Allied Products
974
out of 1,857
48th
Industry group
Drugs
782
out of 1,531
49th
Industry
Pharmaceutical Preparations
609
out of 1,179
48th
Source: SEC filing on April 30, 2018.

Doberstein's colleagues

We found five more compensation records of executives who worked with Stephen K. Doberstein at Nektar Therapeutics in 2015.

2015

Howard Robin

Nektar Therapeutics

Chief Executive Officer

2015

John Nicholson

Nektar Therapeutics

Chief Financial Officer

2015

Gil Labrucherie

Nektar Therapeutics

General Counsel

2015

Maninder Hora

Nektar Therapeutics

Senior Vice President Pharmaceutical Development and Manufacturing Operations

2015

Ivan Gergel

Nektar Therapeutics

Chief Medical Officer

News

You may also like